A prospective, open-label, single-centre, (randomized) study to assess the safety, pharmacokinetics, and pharmacodynamics of daily doses of metyrapone given to patients with adrenocortical incidentaloma and sub-clinical Cushing's syndrome

Trial Profile

A prospective, open-label, single-centre, (randomized) study to assess the safety, pharmacokinetics, and pharmacodynamics of daily doses of metyrapone given to patients with adrenocortical incidentaloma and sub-clinical Cushing's syndrome

Completed
Phase of Trial: Phase I

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Metyrapone (Primary)
  • Indications Adrenocortical carcinoma; Cushing syndrome
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors HRA Pharma
  • Most Recent Events

    • 22 Jan 2014 Planned number of patients changed from 26 to 9 as per United Kingdom Clinical Research Network record.
    • 01 Nov 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top